Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)

Phase 2 Completed 810 enrolled Sanofi

RandomizedParallel-groupDouble-blindTreatment

Summary

Surinabant is a new, potent and selective antagonist for the cannabinoid CB1 receptor, which might be clinically useful in the treatment of dependence to nicotine. The primary study objective is the assessment of efficacy of 3 doses of surinabant on abstinence from smoking in cigarette smokers. The main secondary objectives are the effect of surinabant on body weight and its clinical and biological safety.

Timeline

Start: 2007-01
Primary completion: 2008-04
Completion: 2008-04

Publications

Tonstad S, Aubin HJ. Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial. J Psychopharmacol. 2012 Jul;26(7):1003-9. doi: 10.1177/0269881111431623. Epub 2012 Jan 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	surinabant	Small molecule	2.5 mg	Oral
Comparator	surinabant	Small molecule	5 mg	Oral
Comparator	surinabant	Small molecule	10 mg	Oral

Indications

No indication recorded.